Clinical Trials Logo

Astrocytoma, Grade III clinical trials

View clinical trials related to Astrocytoma, Grade III.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03906448 Terminated - Clinical trials for Astrocytoma, Grade III

FORWARD Optune and Adjuvant TMZ in Grade II/III Astrocytoma

FORWARD
Start date: May 20, 2019
Phase: Phase 2
Study type: Interventional

This is a phase 2, multi-institutional, historically-controlled, study of 100 patients with newly diagnosed Grade II and III astrocytoma comparing the combination of TTFields with adjuvant temozolomide versus temozolomide alone in historical controls after the completion of definitive chemoradiotherapy. Study treatment may continue past first tumor recurrence. The primary endpoint will be overall survival.

NCT ID: NCT02722512 Terminated - Clinical trials for Glioblastoma Multiforme

Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine

Start date: July 2016
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine whether Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine is an feasible and safe treatment for pediatric patients with newly-diagnosed High-Grade Gliomas or recurrent, resectable High-Grade Gliomas and Ependymomas.